Which has preferable valuation and earnings, IMRX or SVRA?

Savara is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immuneering N/A N/A -$56.03M -$1.17 N/A Savara N/A N/A -$118.84M -$0.56 N/A

Is IMRX or SVRA more profitable?

Immuneering's return on equity of -31.93% beat Savara's return on equity. Company Net Margins Return on Equity Return on Assets Immuneering N/A -31.93% -29.92% Savara N/A -87.19% -66.42%

Which has better earnings & valuation, IMRX or CVAC?

CureVac has higher revenue and earnings than Immuneering. Immuneering is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immuneering N/A N/A -$56.03M -$1.17 N/A CureVac $70.74M 14.78 $175.50M $0.72 6.47

Is IMRX or CVAC more profitable?

CureVac has a net margin of 199.92% compared to Immuneering's net margin of 0.00%. CureVac's return on equity of -23.03% beat Immuneering's return on equity. Company Net Margins Return on Equity Return on Assets Immuneering N/A -31.93% -29.92% CureVac 199.92% -23.03% -19.09%

Which has stronger earnings & valuation, CRVS or IMRX?

Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Corvus Pharmaceuticals N/A N/A -$15.28M -$0.52 N/A Immuneering N/A N/A -$56.03M -$1.17 N/A

Is CRVS or IMRX more profitable?

Immuneering's return on equity of -31.93% beat Corvus Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Corvus Pharmaceuticals N/A -38.92% -35.75% Immuneering N/A -31.93% -29.92%

Immuneering (IMRX) Competitors

$4.54 +0.10 (+2.25%)

Closing price 04:00 PM Eastern

Extended Trading

$4.52 -0.02 (-0.35%)

As of 07:46 PM Eastern

Compare

IMRX vs. SVRA, CVAC, DBVT, CRVS, and CRON

Should you buy Immuneering stock or one of its competitors? MarketBeat compares Immuneering with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Immuneering include Savara (SVRA), CureVac (CVAC), DBV Technologies (DBVT), Corvus Pharmaceuticals (CRVS), and Cronos Group (CRON). These companies are all part of the "pharmaceutical products" industry.

How does Immuneering compare to Savara?

Immuneering (NASDAQ:IMRX) and Savara (NASDAQ:SVRA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations.

Immuneering currently has a consensus target price of $16.50, indicating a potential upside of 263.44%. Savara has a consensus target price of $10.14, indicating a potential upside of 75.48%. Given Immuneering's higher possible upside, equities analysts clearly believe Immuneering is more favorable than Savara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuneering	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

67.7% of Immuneering shares are owned by institutional investors. Comparatively, 87.9% of Savara shares are owned by institutional investors. 22.9% of Immuneering shares are owned by insiders. Comparatively, 5.3% of Savara shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Immuneering has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market. Comparatively, Savara has a beta of 0.26, meaning that its share price is 74% less volatile than the broader market.

Savara is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuneering	N/A	N/A	-$56.03M	-$1.17	N/A
Savara	N/A	N/A	-$118.84M	-$0.56	N/A

In the previous week, Immuneering's average media sentiment score of 0.00 equaled Savara'saverage media sentiment score.

Company	Overall Sentiment
Immuneering	Neutral
Savara	Neutral

Immuneering's return on equity of -31.93% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immuneering	N/A	-31.93%	-29.92%
Savara	N/A	-87.19%	-66.42%

Summary

Immuneering beats Savara on 7 of the 11 factors compared between the two stocks.

How does Immuneering compare to CureVac?

Immuneering (NASDAQ:IMRX) and CureVac (NASDAQ:CVAC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, earnings and analyst recommendations.

Immuneering has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market. Comparatively, CureVac has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market.

67.7% of Immuneering shares are owned by institutional investors. Comparatively, 17.3% of CureVac shares are owned by institutional investors. 22.9% of Immuneering shares are owned by company insiders. Comparatively, 2.2% of CureVac shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Immuneering's average media sentiment score of 0.00 equaled CureVac'saverage media sentiment score.

Company	Overall Sentiment
Immuneering	Neutral
CureVac	Neutral

Immuneering presently has a consensus price target of $16.50, indicating a potential upside of 263.44%. CureVac has a consensus price target of $5.50, indicating a potential upside of 18.03%. Given Immuneering's stronger consensus rating and higher possible upside, equities research analysts plainly believe Immuneering is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuneering	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
CureVac	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

CureVac has a net margin of 199.92% compared to Immuneering's net margin of 0.00%. CureVac's return on equity of -23.03% beat Immuneering's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immuneering	N/A	-31.93%	-29.92%
CureVac	199.92%	-23.03%	-19.09%

CureVac has higher revenue and earnings than Immuneering. Immuneering is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuneering	N/A	N/A	-$56.03M	-$1.17	N/A
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47

Summary

CureVac beats Immuneering on 8 of the 14 factors compared between the two stocks.

How does Immuneering compare to DBV Technologies?

Immuneering (NASDAQ:IMRX) and DBV Technologies (NASDAQ:DBVT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, media sentiment, analyst recommendations, earnings and institutional ownership.

Immuneering has higher earnings, but lower revenue than DBV Technologies. Immuneering is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuneering	N/A	N/A	-$56.03M	-$1.17	N/A
DBV Technologies	$5.64M	169.13	-$146.95M	-$4.46	N/A

Immuneering has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market. Comparatively, DBV Technologies has a beta of -0.99, indicating that its share price is 199% less volatile than the broader market.

67.7% of Immuneering shares are held by institutional investors. Comparatively, 71.7% of DBV Technologies shares are held by institutional investors. 22.9% of Immuneering shares are held by insiders. Comparatively, 1.1% of DBV Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Immuneering presently has a consensus price target of $16.50, suggesting a potential upside of 263.44%. DBV Technologies has a consensus price target of $48.50, suggesting a potential upside of 201.06%. Given Immuneering's higher probable upside, equities analysts plainly believe Immuneering is more favorable than DBV Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuneering	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
DBV Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

In the previous week, DBV Technologies had 1 more articles in the media than Immuneering. MarketBeat recorded 1 mentions for DBV Technologies and 0 mentions for Immuneering. DBV Technologies' average media sentiment score of 1.00 beat Immuneering's score of 0.00 indicating that DBV Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Immuneering	Neutral
DBV Technologies	Positive

Immuneering has a net margin of 0.00% compared to DBV Technologies' net margin of -2,895.37%. Immuneering's return on equity of -31.93% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immuneering	N/A	-31.93%	-29.92%
DBV Technologies	-2,895.37%	-129.88%	-88.84%

Summary

Immuneering beats DBV Technologies on 8 of the 15 factors compared between the two stocks.

How does Immuneering compare to Corvus Pharmaceuticals?

Corvus Pharmaceuticals (NASDAQ:CRVS) and Immuneering (NASDAQ:IMRX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation and media sentiment.

Corvus Pharmaceuticals presently has a consensus target price of $33.33, suggesting a potential upside of 163.92%. Immuneering has a consensus target price of $16.50, suggesting a potential upside of 263.44%. Given Immuneering's stronger consensus rating and higher probable upside, analysts plainly believe Immuneering is more favorable than Corvus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Immuneering	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. Comparatively, 67.7% of Immuneering shares are owned by institutional investors. 19.7% of Corvus Pharmaceuticals shares are owned by company insiders. Comparatively, 22.9% of Immuneering shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Corvus Pharmaceuticals had 2 more articles in the media than Immuneering. MarketBeat recorded 2 mentions for Corvus Pharmaceuticals and 0 mentions for Immuneering. Corvus Pharmaceuticals' average media sentiment score of 1.30 beat Immuneering's score of 0.00 indicating that Corvus Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Corvus Pharmaceuticals	Positive
Immuneering	Neutral

Corvus Pharmaceuticals has a beta of 0.84, suggesting that its stock price is 16% less volatile than the broader market. Comparatively, Immuneering has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market.

Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.52	N/A
Immuneering	N/A	N/A	-$56.03M	-$1.17	N/A

Immuneering's return on equity of -31.93% beat Corvus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corvus Pharmaceuticals	N/A	-38.92%	-35.75%
Immuneering	N/A	-31.93%	-29.92%

Summary

Immuneering beats Corvus Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Immuneering compare to Cronos Group?

Immuneering (NASDAQ:IMRX) and Cronos Group (NASDAQ:CRON) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, institutional ownership, dividends, profitability and earnings.

Immuneering has a net margin of 0.00% compared to Cronos Group's net margin of -1.14%. Cronos Group's return on equity of -1.26% beat Immuneering's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immuneering	N/A	-31.93%	-29.92%
Cronos Group	-1.14%	-1.26%	-1.20%

Immuneering presently has a consensus price target of $16.50, suggesting a potential upside of 263.44%. Cronos Group has a consensus price target of $2.30, suggesting a potential downside of 14.81%. Given Immuneering's stronger consensus rating and higher probable upside, research analysts clearly believe Immuneering is more favorable than Cronos Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuneering	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Cronos Group	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Cronos Group has higher revenue and earnings than Immuneering. Immuneering is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuneering	N/A	N/A	-$56.03M	-$1.17	N/A
Cronos Group	$146.59M	6.87	-$9.45M	$0.01	270.00

67.7% of Immuneering shares are owned by institutional investors. Comparatively, 8.7% of Cronos Group shares are owned by institutional investors. 22.9% of Immuneering shares are owned by company insiders. Comparatively, 7.8% of Cronos Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Immuneering has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market. Comparatively, Cronos Group has a beta of 0.89, suggesting that its stock price is 11% less volatile than the broader market.

In the previous week, Cronos Group had 3 more articles in the media than Immuneering. MarketBeat recorded 3 mentions for Cronos Group and 0 mentions for Immuneering. Cronos Group's average media sentiment score of 0.71 beat Immuneering's score of 0.00 indicating that Cronos Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Immuneering	Neutral
Cronos Group	Positive

Summary

Cronos Group beats Immuneering on 9 of the 16 factors compared between the two stocks.

Get Immuneering News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMRX vs. The Competition

Export

Metric	Immuneering	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$287.26M	$3.45B	$6.45B	$12.39B
Dividend Yield	N/A	2.30%	2.69%	5.83%
P/E Ratio	-3.88	19.75	24.92	23.97
Price / Sales	N/A	329.42	528.81	109.59
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	1.34	8.29	10.79	6.50
Net Income	-$56.03M	$23.85M	$3.56B	$336.88M
7 Day Performance	10.73%	5.21%	1.67%	-0.22%
1 Month Performance	-15.77%	2.19%	0.43%	0.77%
1 Year Performance	86.07%	60.99%	32.84%	31.57%

Immuneering Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMRX Immuneering	2.067 of 5 stars	$4.54 +2.3%	$16.50 +263.4%	+73.4%	$287.26M	N/A	N/A	60
SVRA Savara	1.6913 of 5 stars	$5.29 -0.8%	$10.14 +91.9%	+176.2%	$1.08B	N/A	N/A	20
CVAC CureVac	N/A	$4.66 flat	$5.50 +18.0%	N/A	$1.05B	$70.74M	6.47	880
DBVT DBV Technologies	3.5361 of 5 stars	$17.25 -4.8%	$48.50 +181.2%	+67.0%	$1.02B	$5.64M	N/A	80	Positive News
CRVS Corvus Pharmaceuticals	3.8375 of 5 stars	$11.97 +0.6%	$33.33 +178.5%	+217.2%	$1.01B	N/A	N/A	30	Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMRX) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immuneering (IMRX) Competitors

IMRX vs. SVRA, CVAC, DBVT, CRVS, and CRON

How does Immuneering compare to Savara?

Summary

How does Immuneering compare to CureVac?

Summary

How does Immuneering compare to DBV Technologies?

Summary

How does Immuneering compare to Corvus Pharmaceuticals?

Summary

How does Immuneering compare to Cronos Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMRX vs. The Competition

Immuneering Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Immuneering (IMRX) Competitors

IMRX vs. SVRA, CVAC, DBVT, CRVS, and CRON

How does Immuneering compare to Savara?

Do analysts recommend IMRX or SVRA?

Do institutionals & insiders believe in IMRX or SVRA?

Which has more volatility and risk, IMRX or SVRA?

Which has preferable valuation and earnings, IMRX or SVRA?

Does the media refer more to IMRX or SVRA?

Is IMRX or SVRA more profitable?

Summary

How does Immuneering compare to CureVac?

Which has more risk & volatility, IMRX or CVAC?

Do insiders & institutionals believe in IMRX or CVAC?

Does the media refer more to IMRX or CVAC?

Do analysts recommend IMRX or CVAC?

Is IMRX or CVAC more profitable?

Which has better earnings & valuation, IMRX or CVAC?

Summary

How does Immuneering compare to DBV Technologies?

Which has stronger valuation & earnings, IMRX or DBVT?

Which has more risk and volatility, IMRX or DBVT?

Do insiders and institutionals hold more shares of IMRX or DBVT?

Do analysts recommend IMRX or DBVT?

Does the media favor IMRX or DBVT?

Is IMRX or DBVT more profitable?

Summary

How does Immuneering compare to Corvus Pharmaceuticals?

Do analysts rate CRVS or IMRX?

Do insiders & institutionals hold more shares of CRVS or IMRX?

Does the media prefer CRVS or IMRX?

Which has more volatility & risk, CRVS or IMRX?

Which has stronger earnings & valuation, CRVS or IMRX?

Is CRVS or IMRX more profitable?

Summary

How does Immuneering compare to Cronos Group?

Is IMRX or CRON more profitable?

Do analysts prefer IMRX or CRON?

Which has preferable earnings and valuation, IMRX or CRON?

Do insiders and institutionals have more ownership in IMRX or CRON?

Which has more volatility & risk, IMRX or CRON?

Does the media favor IMRX or CRON?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMRX vs. The Competition

Immuneering Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools